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What Does it Tell Us?*John S. Gottdiener, MDSEE PAGE 1034I ncreased LV mass (actually weight) as well as thepattern of that increase has long been associatedwith adverse outcomes in patients with hyper-
tension. Over one-half century ago, it was suggested
that left ventricular hypertrophy (LVH) was a physio-
logical adaptation to increased workload (1,2), and
that the shape (geometry) assumed by the left
ventricle (LV) as it hypertrophied depended on
whether the work imposed on the LV was pressure
or volume overload.
Speciﬁcally, in the presence of pressure overload,
as occurs with hypertension, increased LV mass oc-
curs with normal LV cavity volume but increased wall
thickness (i.e., “concentric” LVH), whereas with vol-
ume overload, as occurs with mitral regurgitation,
increased LV mass occurs with increased LV volume
but normal wall thickness (i.e., “eccentric” LVH). The
so-called eccentricity harkens back to roentgeno-
graphic evaluation of LVH, where the dilated LV is
displaced leftward relative to its normal position in
the chest (3). This basic categorization of LV geometry
in patients with LVH had been further expanded (4–7)
to include the division of eccentric LVH into dilated
and nondilated forms, and a mixed (or concentric
dilated) geometry with both increased wall thickness
relative to cavity size and LV dilation.
Changes in LV geometry can be considered to be
“adaptive” in that the increased wall thickness of
concentric hypertrophy acts to normalize wall stress
while the increased myocyte length in volume over-
load helps preserve stroke volume (8). These theo-
retical considerations aside, early echocardiographic
studies (9) showed that concentric LVH in fact was*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
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paper to disclose.associated with greater, not lesser, risk of death and
morbidity than eccentric LVH, itself associated with
increased risk. Moreover, even individuals with
concentric remodeling deﬁned as normal LV mass,
but increased relative wall had increased risk of
adverse events. However, geometric patterns of LVH
are associated with differing risk factors, including
the degree of increase in LV mass, and subsequent
studies (10–12) with greater power and statistical
adjustment for confounders suggested that LV
geometry may not confer prognostic beneﬁt inde-
pendent of LV mass and traditional risk factors. Apart
from the potential value of LV geometry to identify
risk, LV geometry may be useful to predict treat-
ment responses to antihypertensive treatment (13),
and hypertension treatment may favorably alter
LV geometry (14).In this issue of iJACC, Garg et al. (15) present data
from 2,458 participants (31% hypertensive, 10% dia-
betic) in the Dallas Heart Study who underwent car-
diac magnetic resonance (CMR) for assessment of LV
mass and geometry. Participants were followed for a
median of 9 years for the primary outcome of incident
heart failure or death. Admirably, partition values for
LV mass and geometry were internally derived from
healthy study subjects within the Dallas Heart Study,
and classiﬁcation of LVH geometry was extended
beyond previous methods.
Utilizing measured average wall thickness, LV
diastolic volume, and computed concentricity (a
measure of LV mass/volume ratio), the authors
deﬁned 4 categories of LVH and compared outcomes
in these categories to the reference category of
normal LV mass. Concentric remodeling was not
deﬁned or evaluated. The greatest risk for the com-
bined endpoint of cardiovascular death or heart fail-
ure was in the 4% of participants with LVH who had
dilated eccentric LVH, followed by the 1% with a
mixed pattern of LVH characterized by both increased
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1043concentricity and LV dilation. In contrast, the risk of
the combined endpoint did not achieve signiﬁcance
in the largest group of participants with LVH, that is,
the 55% with indeterminate LVH (i.e., not meeting
criteria for LV dilation or increased concentricity),
and was modest in the 40% of participants with the
thick-walled form of concentric LVH. These ﬁndings
are consistent with those recently reported by in-
vestigators who applied the Dallas Heart Study clas-
siﬁcation of LVH to echocardiographic evaluation of
an open hypertension registry of 8,848 subjects in
Southern Italy (12).
The authors are to be congratulated for a carefully
conducted study of a large and well-characterized
population-based cohort using CMR, a more difﬁcult
but also a more accurate and reproducible technique
for measurement of LV mass and presumably LV
geometry than echocardiography, which is utilized in
most clinical studies of LVH.
However, there are several caveats regarding the
ﬁndings of this study. Even with a 9-year follow-up of
a large cohort, the number of events (n ¼ 81) was too
low to separate incident heart failure from cardio-
vascular death. Given the relatively young age of the
cohort at the time of study, a longer duration of
follow-up would have been necessary to capture the
maximum number of events, and the young age of the
subjects challenges the generalizability of the ﬁnd-
ings to an older population with higher disease
burden. The analyses did not include potential con-
founders, including LV mass and volume, that were
unequally distributed across the risk gradient of
geometric subtypes. Hence, it remains uncertain
whether association of LV geometry with adverse
outcomes is greater than simply using LV mass.
Importantly, the high-risk LVH subgroups only
accounted for slightly less than one-half of events. The
plurality of events (41%) occurred in the reference
group with normal LV mass and normal geometry, and
the majority of events occurred in structurally normal
or low-risk groups. Hence, although the investigators
identiﬁed geometric subgroups of individuals with
LVH at particularly high relative risk, the actualprevalence of high-risk groups among those with LVH
was low (e.g., mixed LVH only had 7 subjects). Hence,
the population-attributable risk of cardiovascular
death or heart failure in groupswith high relative risk is
low.
Nonetheless, the ﬁndings of this and other studies
of cardiac end-organ response to hypertension are of
great interest and reintroduce the long-standing
hope that tailoring the treatment of hypertension to
cardiac phenotype, in this case LVH and its geometric
subtypes determined by CMR, could improve out-
comes in those who are at high risk and avoid un-
necessary treatment in those at low risk. However,
this hypothesis has never been adequately tested.
One important limitation to the wider use of CMR
is cost. In the United States alone, approximately 76.4
million adults have hypertension (16). At even the
arguably modest current Medicare/Medicaid reim-
bursement for basic cardiac CMR of $356.61 (CPT code
35550), 1 study per patient with hypertension would
cost over $27.3 billion, and the cost of sequential
studies to monitor treatment effects would be truly
astronomic.
As has been the case with the use of echocardiogra-
phy in hypertension (17), the value of CMR will be
difﬁcult to establish. Moreover, existing strategies
that are not guided by imaging for lowering blood
pressure have been effective in reducing mortality and
morbidity. Hence, it will be difﬁcult to justify large-
scale funding of randomized controlled trials designed
to determine the practicability and efﬁcacy of therapy
targeted to cardiac structural phenotype. Nonetheless,
the pathophysiological insights obtained from this and
other studies of cardiac phenotypes in hypertension
may help researchers to develop reﬁned risk models
that could be helpful, particularly if unnecessary
treatment could be avoided in subgroups of patients
with elevated blood pressure but low risk.
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